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Background: Despite guideline recommendations, dual antiplatelet therapy (DAPT) is
frequently used for longer than 1 year after an acute coronary syndrome (ACS) event.
In Asia, information on antithrombotic management patterns (AMPs), including DAPT
post discharge, is sparse. This analysis evaluated real-world AMPs up to 2 years post
discharge for ACS.
Hypothesis: There is wide variability in AMP use for ACS management in Asia.
Methods: EPICOR Asia (NCT01361386) is a prospective observational study of
patients discharged after hospitalization for an ACS in eight countries/regions in Asia,
followed up for 2 years. Here, we describe AMPs used and present an exploratory
analysis of characteristics and outcomes in patients who received DAPT for
≤12 months post discharge compared with >12 months.
Results: Data were available for 12 922 patients; of 11 639 patients discharged on
DAPT, 2364 (20.3%) received DAPT for ≤12 months and 9275 (79.7%) for
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>12 months, with approximately 60% still on DAPT at 2 years. Patients who received
DAPT for >12 months were more likely to be younger, obese, lower Killip class, resi-
dent in India (vs China), and to have received invasive reperfusion. Clinical event rates
during year 2 of follow-up were lower in patients with DAPT >12 vs ≤12 months, but
no causal association can be implied in this non-randomized study.
Conclusions: Most ACS patients remained on DAPT up to 1 year, in accordance with
current guidelines, and over half remained on DAPT at 2 years post discharge.
Patients not on DAPT at 12 months are a higher risk group requiring careful
monitoring.
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1 | INTRODUCTION
Acute coronary syndromes (ACS) are a leading cause of morbidity and
mortality in the Asia-Pacific (APAC) region.1,2 Although APAC guide-
lines are generally comparable to those from Europe and the United
States, a higher proportion of patients in the region receive solely
medical management after hospitalization for an ACS, as opposed to
invasive procedures. Post-discharge medical management can vary
considerably across Asia, as well as ACS-related outcomes, which are,
overall, poorer in the APAC region when compared with global out-
comes.1-3 The relationship between patterns of medical management
post-ACS discharge and ACS-related outcomes in Asia remains
unclear.
The pivotal CHARISMA (Clopidogrel for High atherotherombotic
Risk and Ischemic Stablization, Management, and Avoidance) trial
demonstrated that dual antiplatelet therapy (DAPT) with clopidogrel
plus aspirin for a median of 28 months was effective in reducing a
composite endpoint (myocardial infarction [MI], stroke, or death from
cardiovascular causes) compared with aspirin alone in patients with
clinically evident atherothrombosis, but not the overall population
with either clinically evident cardiovascular disease or multiple risk
factors.4 A subsequent subgroup analysis from CHARISMA confirmed
the benefit of DAPT in patients with prior MI, ischemic stroke, or
symptomatic peripheral arterial disease, with a significant reduction in
the composite endpoint but no difference in severe bleeding com-
pared with aspirin alone.5 As a result of this and subsequent studies,
recent national and international guidelines recommend the use of
DAPT for patients surviving an ACS, including those with ST-elevation
myocardial infarction (STEMI) or non-ST-elevation ACS (NSTE-ACS),
the latter comprising non-ST-elevation myocardial infarction
(NSTEMI) and unstable angina (UA).6-12 In general, guidelines recom-
mend the use of DAPT for up to 12 months post-ACS, with a switch
to single antiplatelet therapy (SAPT) as appropriate, if bleeding risk is
increased. However, guidelines are emerging that support prolonged
DAPT in patients with ACS deemed to be at high risk of further
ischemic events, particularly where the risk of ischemic events and
cardiovascular death outweigh the risk of life-threatening
bleeding.12-14
A recent real-world observational study showed that the propor-
tion of patients receiving DAPT for more than a year after discharge
post MI was higher in the APAC region (39%) than in Europe (12%),15
but data describing the impact of prolonged DAPT on outcomes in
Asia are limited. The real-world EPICOR Asia (long-tErm follow-uP of
antithrombotic management patterns In acute CORonary syndrome
patients in Asia) study (NCT01361386) followed ACS survivors across
eight countries and regions in Asia for up to 2 years after an ACS
event.3 EPICOR Asia had two co-primary outcomes analyses per-
formed; the first, reported elsewhere, examined the relationship
between patient characteristics and long-term outcomes according to
index event diagnosis.16 The second, reported here, examined the
relationship between patient characteristics and antithrombotic man-
agement patterns (AMPs) used, and observed long-term clinical out-
comes. Economic outcomes have also been examined.17,18
2 | METHODS
2.1 | Study design and patients
Details of the EPICOR Asia study design and baseline patient charac-
teristics have been reported previously.3 EPICOR Asia was a multi-
national, prospective, observational cohort study with a 2-year
post-discharge follow-up period, which described both in-hospital
and post-discharge AMPs in ACS and associated clinical outcomes in
eight countries and regions in Asia. Between June 2011 and May
2012, patients surviving initial hospitalization for ACS were enrolled
from 218 centers in China, Hong Kong, India, Malaysia, Singapore,
South Korea, Thailand, and Vietnam. Adults aged ≥18 years were
enrolled if hospitalized for an ACS event within 48 h of symptom
onset (STEMI, NSTEMI, or UA) and survived to discharge.
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Overall, 13 005 patients were enrolled in EPICOR Asia, most from
China (63.6%) and India (19.1%). Among these, 12 922 were eligible
for inclusion; 83 patients were excluded (19 did not survive to dis-
charge, ie, were incorrectly enrolled, and 64 were excluded—from one
site—due to critical data quality issues). Data on patient demographics,
medical history, and management were collected from symptom onset
to discharge and AMPs at hospital discharge and post discharge by
means of telephone interviews scheduled at 6 weeks and then every
3 months post index event until 2 years.
Study procedures adhered to International Conference on Har-
monization (ICH) Good Clinical Practice guidance, the Declaration
of Helsinki, and local regulations, and Institutional Review Board/
Ethics Committee approval was obtained at each participating cen-
ter in each country (https://astrazenecagrouptrials.pharmacm.com/
ST/Submission/Search). All patients provided written informed
consent.
The aim of this analysis was to characterize oral AMPs (anti-
platelet and anticoagulant) at discharge and during a 2-year follow-up
period. Patterns of antiplatelet therapy (none, aspirin only, P2Y12
receptor antagonist only [eg, clopidogrel or prasugrel], other SAPT,
DAPT with aspirin plus P2Y12 receptor antagonist, other DAPT, or
triple antiplatelet therapy [TAPT]), and anticoagulant (anticoagulant
alone or anticoagulant plus antiplatelet therapy) were evaluated at dis-
charge, and at 1.5, 3, 6, 9, 12, 18, and 23 months post discharge. In
practice, final interviews were conducted within ±2 weeks of the
24-month timepoint, hereafter referred to as 24 months or 2 years.
Where appropriate, to avoid “loss” of patients whose last interview
was 1 or 2 weeks prior to the 24-month timepoint, medication status
at 23 months is reported. For patients on SAPT or DAPT at discharge,
the proportions remaining on SAPT or DAPT, or who switched to
another antiplatelet pattern, were evaluated. Possible associations
between baseline factors, SAPT use at discharge, and DAPT duration
>12 months vs ≤12 months were investigated.
Time from discharge to event (including time to first major bleed-
ing event) was assessed, including analysis by EPICOR 2-year risk
score, based on previously published data from the EPICOR19 and
EPICOR Asia studies.20 Clinical events were death and the composite
of death, non-fatal MI, or non-fatal ischemic stroke (with or without
major bleeding).
All outcomes were validated as previously described.3
2.2 | Statistical analysis
Patient characteristics are described using appropriate descriptive sta-
tistics, with P values derived from chi-square test for categorical vari-
ables, two-sample t-test for comparison of means, and Wilcoxon test
for comparison of medians. Logistic regression models were used to
evaluate relationships between baseline characteristics, and (a) SAPT
use at discharge, and (b) DAPT use >12 vs ≤12 months, with odds
ratio (OR) and two-sided 95% confidence interval (CI) presented. A
stepwise model selection was made with the P value cut-offs for
selection at P < .01 and retention at P < .20.
Data are presented in terms of OR and associated two-sided 95%
CIs and P values. The proportion of patients discharged on DAPT who
remained on DAPT beyond 12 months is also described by percentile
(≤60th, >60th and ≤80th, >80th and ≤90th, and >90th, referred to as
low, moderate, high, and very high risk categories, respectively) for
each EPICOR 2-year risk score category.
An exploratory analysis of time from 12 months after discharge
to each clinical event during the second year of follow-up by DAPT
duration (>12 or ≤ 12 months) was made based on Cox proportional
hazards models with stepwise model selection with DAPT duration
(>12 or ≤12 months), index event diagnosis, age (<60, 60 to <75, and
≥75 years), gender, country group (defined as: China; India; Hong
Kong, Singapore, South Korea [HK/Si/SK]; and Malaysia, Thailand,
and Vietnam [Ma/Th/Vie]), and in-hospital management always kept
in the model. The data are presented in terms of hazard ratio (HR) and
two-sided 95% CIs.
Statistical analysis was performed using SAS version 9.3 or later
(SAS Institute Inc., Care, North Carolina).
3 | RESULTS
3.1 | Patient characteristics
Details of baseline patient characteristics have been published previ-
ously.3 Of 12 922 patients enrolled in EPICOR Asia, most were from
China (63.6%) and India (19.1%). Patients had a mean age of 60 years,
76.3% were male, 27.2% had prior cardiovascular disease (CVD), and
80.5% had cardiovascular risk factors (53.0% hypertension, 17.0%
hypercholesterolemia, 24.5% diabetes, 8.4% family history of coro-
nary artery disease [CAD], 5.3% obesity, and 33.9% current smokers).
The final diagnosis was STEMI in 51.2%, NSTEMI in 19.9%, and UA in
28.9% of patients. Patients from all countries showed a relatively high
prevalence of cardiovascular risk factors, notably, obesity (body mass
index [BMI] >30 kg/m2) in patients from Malaysia and Singapore.
Most had undergone coronary revascularization, except those from
India and Malaysia.
3.2 | Antiplatelet therapy at discharge and
follow-up
Baseline demographics by discharge antiplatelet medication and by
DAPT duration ≤12 or >12 months (in patients discharged on
DAPT) are shown in Table 1 (patients who survived at least
12 months) and Supporting information, Table S1 (all patients),
available in the Supporting information in the online version of this
article. Of the 12 922 patients, 1283 (9.9%) were discharged on
SAPT or no antiplatelet therapy, and 11 639 (90.1%) on DAPT
(Supporting information, Table S2), consisting of aspirin and a
P2Y12 receptor antagonist in 88.8% of cases (Supporting informa-
tion, Table S3). By 12 months post discharge, 86.4% were still
receiving DAPT, which decreased to 62.5% by 2 years (Figure 1).
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TABLE 1 Demographics, index diagnosis, and general health status of patients discharged on DAPT who survived ≥12 months and continued
on DAPT for ≤12 vs >12 monthsa




(n = 9275) P value
Duration of DAPTa, months; median (IQR) 7.7 (3.0-11.6) 23.6 (18.1-23.8)
Age group, years .0001
≤59 716 (46.4) 4564 (50.2)
60-74 617 (40.0) 3681 (39.7)
≥75 209 (13.6) 940 (10.1)
Male 1149 (74.5) 7249 (78.2) .002
Final diagnosis of index event .046
STEMI 779 (50.5) 4940 (53.3)
NSTE-ACS 763 (49.5) 4335 (46.7)
BMIb, mean (SD) 24.5 (3.3) 24.8 (3.6) .002
BMIb .26
<25 kg/m2 (underweight/normal) 867 (59.0) 4893 (56.9)
25 to <30 kg/m2 (overweight) 524 (35.7) 3182 (37.0)
≥30 kg/m2 (obese) 78 (5.3) 518 (6.0)
Killip class .02
I 787 (51.0) 4976 (53.7)
II 158 (10.3) 983 (10.6)
III 39 (2.5) 319 (3.4)
IV 37 (2.4) 230 (2.5)
Missing 521 (33.8) 2767 (29.8)
Left bundle branch block 12 (0.8) 157 (1.8) .009
Ejection fraction .43
<30% 25 (1.6) 151 (1.6)
30%-40% 68 (4.4) 448 (4.8)
≥40% 981 (63.6) 5699 (61.4)
Missing 468 (30.4) 2977 (32.1)
Any CVD risk factorsb 1011 (66.0) 6072 (65.9) .92
Hypertension 831 (54.3) 4859 (52.8) .28
Hypercholesterolemia 273 (18.5) 1617 (18.1) .72
Diabetes 335 (22.0) 2245 (24.5) .032
Family history of CAD 146 (10.1) 798 (9.1) .21
Current smoker 543 (35.2) 3700 (43.1) .81
Any prior CVDb 439 (28.7) 2416 (26.7) .09
MI 149 (9.8) 828 (9.2) .42
Prior PCI 125 (8.2) 694 (7.7) .46
Prior CABG 17 (1.1) 121 (1.3) .49
CAG diagnostic for CAD 164 (10.8) 836 (9.3) .06
Angina 247 (16.2) 1410 (15.6) .53
Heart failure 37 (2.5) 194 (2.2) .47
Atrial fibrillation 28 (1.9) 103 (1.1) .022
TIA/stroke 67 (4.4) 386 (4.3) .79
PVD 12 (0.8) 70 (0.8) .93
Chronic renal failure 34 (2.3) 122 (1.4) .007
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Aspirin was the most common antiplatelet prescribed at discharge
as monotherapy, being used in 5.3% of patients, which increased
to 31.2% at 2 years (Supporting information, Table S3). Patients
discharged on DAPT were more likely to switch to SAPT (1.6%,
11.3%, and 32.5% at 1.5, 12, and 24 months, respectively), than to
no therapy (0.4%, 2.2%, and 4.9%, respectively). Use of TAPT
and/or an anticoagulant was minimal, with low usage throughout
(Supporting information, Table S3).
Of those patients discharged on SAPT (n = 1121), 90.2%
remained on SAPT at 12 months, and 85.4% at 2 years; these patients
were more likely to switch to no antiplatelet (2.0%, 8.8%, and 13.6%
at 1.5, 12, and 24 months, respectively) than to DAPT (0.5%, 1.0%,
TABLE 1 (Continued)




(n = 9275) P value
Any CV medicationb 584 (38.8) 3231 (36.5) .08
Any antiplatelet 392 (26.3) 2097 (23.9) .045
Aspirin 374 (25.1) 2028 (23.1) .10
Clopidogrel 135 (9.1) 805 (9.2) .90
β-blocker 251 (17.6) 1327 (15.4) .042
ACEi/ARB 234 (16.4) 1335 (15.5) .43
Statin 241 (16.8) 1255 (14.6) .031
In-hospital proceduresb
PCI/CABG 932 (60.9) 7127 (78.1) <.0001
Reperfusion (primary PCI or fibrinolysis) 998 (65.4) 7445 (81.5) <.0001
Any drug-eluting stent 797 (51.7) 6381 (68.8) <.0001
In-hospital MI/recurrent ischemia/heart failure/
cardiogenic shock/arrhythmiab
266 (17.4) 1179 (12.9) <.000
Country groupc <.0001
China (n = 7049) 1099 (71.3/15.6) 5950 (64.2/84.4)
India (n = 1832) 140 (9.1/7.6) 1692 (18.2/92.4)
South Korea, Hong Kong, Singapore (n = 847) 129 (8.4/15.2) 718 (7.7/84.8)
Malaysia, Thailand, Vietnam (n = 1089) 174 (11.3/16.0) 915 (9.9/84.0)
Time from symptom onset to admission, hours;
median (IQR)
5.3 (2.2-17.2) 5.7 (2.3-18.0) .19
Time from admission to reperfusion, hours; median
(IQR)
10.3 (1.2-97.3) 14.0 (1.4-91.9) .37
Time from symptom onset to reperfusion, hours;
median (IQR)
24.0 (4.2-112.7) 27.1 (5.7-12.0) .009
Length of hospital stay, days; median (IQR) 9.0 (6.0-13.0) 8.0 (5.0-12.0) .004
Dependence at discharge .05
No dependence 1471 (95.4) 8698 (93.8)
Non-severe dependence 66 (4.3) 537 (5.8)
Severe dependence 5 (0.3) 40 (0.4)
EQ-5D overall health state at discharge, mean (SD) 79.2 (12.9) 78.9 (13.8) .46
Abbreviations: ACEi/ARB, angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker; BMI, body mass index; CABG, coronary artery bypass
graft; CAD, coronary artery disease; CAG, coronary angiogram; CHD, coronary heart disease; CV, cardiovascular; CVD, cardiovascular disease; DAPT, dual
antiplatelet therapy; EQ-5D, EuroQol-5 Dimensions; IQR, interquartile range; MI, myocardial infarction; NSTE-ACS, non-ST elevation acute coronary syn-
drome; SD, standard deviation; STEMI, ST-elevation myocardial infarction; PCI, percutaneous coronary intervention; TAPT, triple antiplatelet therapy; TIA,
transient ischemic attack. Values are n (%) unless otherwise indicated.
aIncludes patients reported as taking two or more antiplatelets at discharge (ie, including TAPT). DAPT duration was defined as time from discharge to the
last use of two or more antiplatelets, not accounting for interruptions.
bAt discharge, data were missing for 879 patients for BMI, 68 patients for any CVD risk factors, 244 patients for any prior CVD, 562 patients for any CV
medication, 172 patients for in-hospital PCI/CABG, 169 patients for primary PCI/fibrinolysis, and 128 patients for in-hospital MI/recurrent ischemia/heart
failure/cardiogenic shock/arrhythmia.
cPercentages shown are within DAPT duration group/within each country or region.
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and 1.1%, respectively). No patient discharged on SAPT received
TAPT post discharge.
Of the 11 817 patients discharged on DAPT who survived at least
12 months, 1542 received DAPT for ≤12 months (median 7.7 months)
and 9275 for more than 12 months (median 23.6 months) (Table 1).
Twelve-month survivors who received DAPT for more than
12 months post discharge, compared with ≤12 months, were youn-
ger, had a higher BMI, and were more likely to be male and to have
received an in-hospital invasive procedure for the index event
(Table 1 and Supporting information, Table S1). They were less likely
to have received prior antiplatelet medication, experienced an in-
hospital cardiovascular event, had prior atrial fibrillation, or to have
impaired renal function. Median time from symptom onset or
admission to reperfusion (by intervention or fibrinolysis) was similar
regardless of duration of DAPT use, whereas the overall time from
symptom onset to reperfusion was shorter in the DAPT ≤12 months
cohort (Table 1 and Supporting information, Table S1). Conversely,
median length of hospital stay was shorter with DAPT >12 vs
≤12 months.
Multivariable analysis indicated that significant predictors of
DAPT duration >12 vs ≤12 months in patients who survived at least
12 months were younger age, obesity, residency in India vs China, any
drug-eluting stent (DES) placement, and in-hospital percutaneous cor-
onary intervention (PCI)/coronary artery bypass graft (CABG)
(Table 2). In contrast, patients who had an in-hospital cardiovascular
event were less likely to be on DAPT >12 months. The greatest
F IGURE 1 Antithrombotic
management status of patients from
discharge up to 2 years post discharge.
Abbreviations: AC, anticoagulant; DAPT,
dual antiplatelet therapy; SAPT, single
antiplatelet therapy
TABLE 2 Logistic multivariable
regression analysis for predictors of
DAPT duration >12 months vs
≤12 months in patients who survived
≥12 months
Factor ORa 95% CI P value
Age group, vs ≤59 years <.0001
60-74 0.88 0.79, 0.98
≥75 0.68 0.58, 0.79
Bodyweight (BMI, kg/m2), vs <25
(underweight/normal)
<.05
Overweight (mean BMI, 25-30 kg/m2) 1.13 1.02, 1.25
Obese (BMI >30 kg/m2) 1.15 0.93, 1.43
Any drug-eluting stent, vs no 1.67 1.39, 2.00 <.0001
In-hospital cardiovascular event, vs no 0.68 0.59, 0.77 <.0001
In-hospital PCI/CABG, vs no 1.53 1.28, 1.85 <.0001
Country group, vs China <.0001
India 1.75 1.50, 2.04
Hong Kong, Singapore, and South Korea 1.05 0.87, 1.27
Malaysia, Thailand, and Vietnam 1.27 1.08, 1.48
Abbreviations: BMI, body mass index; CABG, coronary artery bypass graft; CI, confidence interval; DAPT, dual antiplatelet therapy; OR, odds ratio; PCI,
percutaneous coronary intervention; TAPT, triple antiplatelet therapy. Stepwise selection procedure using logistic regression model for likelihood of DAPT
duration >12 months (vs ≤12 months); DAPT duration was defined as time from discharge from the index hospitalization to the last use of ≥2 antiplatelets
(ie, including TAPT), not accounting for interruptions. Continuous variables replaced with categorical equivalents included: BMI (<25, 25-30, ≥30 kg/m2;
retained) and initial creatinine (< and ≥1.2 mg/dL; not retained).
aOR > 1 indicates greater likelihood of DAPT duration >12 months.
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predictor of SAPT/no antiplatelet vs DAPT at discharge was anticoag-
ulant use (Supporting information, Table S4). Other significant predic-
tors of SAPT/no antiplatelet use were any degree of physical
dependence (vs no dependence), Killip class >I, female sex, and resi-
dency in India vs China, whereas patients with ejection fraction ≥30%
and those who underwent in-hospital intervention (PCI/CABG) were
more likely to be discharged on DAPT.
When evaluated in terms of EPICOR 2-year risk score, the num-
ber of patients remaining on continuous DAPT were generally lower
as risk percentiles increased, up to the 15-month visit, although this
pattern was less apparent thereafter (Figure 2; Supporting informa-
tion, Table S5). There was greater loss to follow-up at each timepoint
in the highest percentile group (>90th).
When comparing the groups who were treated with DAPT
>12 months vs ≤12 months in the 12-month survivors, the hazard of
composite of death, MI, and stroke was much lower in the group
treated with DAPT >12 months (adjusted HR 0.39) (Figure 3), seem-
ingly lower than would be expected should treatment allocation bias
and confounding have been sufficiently reduced. This was also appar-
ent insofar as the adjusted HR was quite similar to the unadjusted HR
(0.33). The same trend was shown for both mortality and when major
bleeding was added to the above composite. Similarly, the incidence
of each endpoint (number of first events per 100 patient-years) was
lower in the DAPT >12 months population.
4 | DISCUSSION
The EPICOR Asia study revealed that, despite guideline recommenda-
tions at the time of the study, most patients with ACS in Asia
F IGURE 2 Proportion of patients on
continuous DAPT at each visit according
to EPICOR 2-year risk categoriesa.
Low risk, ≤60th percentile; moderate risk,
>60th to ≤80th percentile; high risk,
>80th to ≤90th percentile; and very high
risk, >90th percentile of the EPICOR
2-year risk score. Data at each time point
are percentages of patients still on DAPT
out of total discharged on DAPT in each
risk category. aIncludes patients reported
as taking two or more antiplatelets
(ie, including triple antiplatelet therapy).
Abbreviations: DAPT, dual antiplatelet
therapy; EPICOR, long-tErm follow-up of
antithrombotic management Patterns In
acute CORonary syndrome
F IGURE 3 Hazard ratio between
DAPT use >12 months and ≤12 months
for clinical events during the second year
of follow-up in patients who survived
≥12 months.
aNumber of (first) events per 100 patient-
years. Abbreviations: CI, confidence
interval; DAPT, dual antiplatelet therapy;
HR, hazard ratio; IS, ischemic stroke; MI,
myocardial infarction
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remained on DAPT beyond 12 months. Logistic multivariable regres-
sion analysis indicated that these patients tended to be younger,
obese, lower Killip class, resident in India (vs China), and to have
received invasive reperfusion and DES placement, and they were less
likely to have had an in-hospital cardiovascular event. The approxi-
mate 60% observed rate of prolonged DAPT use (>12 months post-
discharge) in this study is generally higher than that reported across
the APAC region (39%) and Europe (12%), albeit with considerable
between-country variability.1,2,15 Similarly, while 75% of the EPICOR
Asia overall DAPT cohort underwent PCI/CABG for the index event,
it has been reported elsewhere that up to 80% of patients with ACS
in the APAC region are managed non-invasively.1 In EPICOR Asia,
event rates continued to accrue throughout the 2-year follow-up
period post discharge, with higher rates in the initial period and a
steady increase during subsequent months up to the end of
follow-up.
Overall, patients in whom DAPT was used for more than
12 months appeared to show lower rates of cardiovascular events
and mortality compared with those in whom DAPT cessation occurred
earlier, with no apparent increase in risk of major bleeding. However,
any observed association between event rates and DAPT duration
must be interpreted with caution, due to the possible presence of
confounding factors. In particular, treatment allocation bias and con-
founding occurring 12 months post discharge, that were not explained
by the discharge variables, could not be adjusted for.
A recent randomized, non-inferiority study evaluating 6 months
vs ≥12 months of DAPT following PCI with DES placement in 2712
South Korean patients with ACS (the SMART-DATE [Safety of
6-month Duration of Dual Antiplatelet Therapy After Acute Coro-
nary Syndromes] study) observed a higher rate of MI in the short-
duration DAPT population over an 18-month follow-up period
(1.8% vs 0.8%; HR 2.41, 95% CI 1.15-5.05; P = .02).21 Although no
significant differences were evident between groups in terms of
outcomes, the authors concluded that short-term DAPT may pre-
sent risks in patients with ACS who have undergone current-
generation DES placement. In contrast, two meta-analyses of
randomized controlled trials, published in 2018, suggested that
short-term (≤6 months) DAPT post-DES placement may provide
benefit compared with DAPT up to 12 months towards reducing
bleeding risk.22,23 Potential benefit from short-term DAPT after
DES placement in older vs younger patients was also suggested.23 It
should be noted, however, that these analyses included patients
with both stable CAD and ACS. Another meta-analysis of random-
ized trials found that DAPT duration over 1 year was associated
with significant reductions in ischemic events (cardiovascular death,
recurrent MI, and stroke) compared with aspirin alone in stabilized
high-risk patients with prior MI.24 Major bleeding was increased
when DAPT was continued for more than a year but not fatal bleed-
ing or non-cardiovascular death.
Recently, using data from more than 23 000 patients included in
both the EPICOR Asia and the EPICOR study (NCT01171404), char-
acteristics and outcomes of medically managed patients with NSTE-
ACS and predictors of 1- and 2-year post-discharge mortality risk
were identified.20,25,26 In this analysis, when evaluated in terms of
EPICOR 2-year risk score, the number of patients remaining on DAPT
during follow-up was generally reduced as risk percentiles increased,
particularly up to the 15-month visit.
Several potential limitations of the EPICOR Asia study include
most patients being enrolled from China, resident in metropolitan
areas, and enrolled at well-equipped centers, thus not being fully rep-
resentative of the region. Such considerations may partly explain dis-
crepancies in these data and earlier reports for the APAC region;
reliance on earlier data must factor in possible greater uptake of
evidence-based guidelines, specifically, the use of both DAPT and PCI,
as evidenced in China.27 Also, it is possible that the exclusion of data
for patients who did not survive to hospital discharge may have
resulted in underestimation of overall mortality from ACS. It should
also be emphasized again that a causal relationship between DAPT
duration and clinical event rates in this analysis cannot be inferred, as
the population was non-randomized, with many possible reasons for
discontinuing DAPT (eg, patients who stopped DAPT early may have
had associated clinical comorbidities or socio-economic issues). Also,
as mentioned previously, there are potential confounding factors that
we were not able to adjust for, and landmark analyses in a real-would
registry study may not account for survivor bias that might influence
the final results. Finally, the study was carried out prior to the wide
availability of the more potent oral antiplatelet agents, prasugrel and
ticagrelor. The long-term (>1 year) use of DAPT with ticagrelor plus
aspirin has been shown to significantly reduce the risk of subsequent
cardiovascular events in the PEGASUS-TIMI 54 (Prevention of Cardio-
vascular Events in Patients with Prior Heart Attack Using Ticagrelor
Compared to Placebo on a Background of Aspirin-Thrombolysis in
Myocardial Infarction 54) trial in patients with prior MI,28 and in the
THEMIS (The Effect of Ticagrelor on Health Outcomes in Diabetes
Mellitus Patients Intervention Study) trial in diabetic patients with
stable coronary artery disease (without a history of MI or stroke),29
albeit with increased risk of major bleeding in each case. The
THEMIS-PCI study demonstrated a more favorable net clinical benefit
with long-term DAPT in diabetic patients with rather than without
prior PCI.30 Recent real-world data from the RENAMI (Registry of
New Antiplatelets in patients with Myocardial Infarction) registry in
6 European countries also demonstrated that DAPT duration >1 year
with either prasugrel or ticagrelor in propensity-score matched ACS
patients significantly reduced all-cause death, cardiovascular death,
and recurrent MI compared with DAPT <1 year after 20 months of
follow-up, but with increased risk of bleeding in women and older
patients (>75 years).31
In summary, this analysis of results from EPICOR Asia has shown
that most patients surviving an ACS in Asia were discharged on DAPT,
and more than half remained on DAPT for up to 2 years of follow-up.
Prolonged DAPT was more likely to be employed in younger patients,
and those with DES placement or in-hospital PCI/CABG, and less
likely to be used in China compared with India. Patients in whom
DAPT treatment was stopped earlier than 12 months post discharge
had higher rates of mortality and adverse cardiovascular events. While
a causal relationship between outcomes and DAPT duration in this
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study cannot be inferred, the findings do suggest that patients who
receive DAPT for ≤12 months are a high-risk population and may
require greater medical attention after discontinuation of DAPT than
patients who receive DAPT for longer.
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